NCT01995201 - A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis | Biotech Hunter

Enrollment

401

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

July 31, 2015

Study Completion Date

March 31, 2016

Conditions

Rheumatoid Arthritis

Interventions

DRUG

DMARD

non-biological disease-modifying antirheumatic drugs at stable dose

DRUG

methotrexate

stable dose

DRUG

tocilizumab [RoActemra/Actemra]

162 mg subcutaneously (SC) qw, Weeks 1-24

DRUG

tocilizumab [RoActemra/Actemra]

162 mg SC qw or q2w, Weeks 24-48

DRUG

tocilizumab [RoActemra/Actemra]

162 mg SC qw, Weeks 24-48

Trial Locations (53)

0

Limerick

4

Dublin

24

Dublin

11407

Jerez de la Frontera

14004

Córdoba

15006

A Coruña

15706

Santiago de Compostela

18014

Granada

19002

Guadalajara

20080

Donostia / San Sebastian

28006

Madrid

28007

Madrid

28034

Madrid

28041

Madrid

28046

Madrid

28222

Madrid

28905

Madrid

28942

Fuenlabrada

29009

Málaga

30120

El Palmar

30203

Cartagena

35016

Las Palmas de Gran Canaria

37007

Salamanca

38010

Santa Cruz de Tenerife

39300

Torrelavega

41009

Seville

41010

Seville

41013

Seville

43700

Tarragona

45004

Toledo

46009

Valenica

46010

Valencia

48013

Bilbao

50009

Zaragoza

Unknown

Co Leitrim

Cork

Waterford

2801-951

Almada

3814-501

Amadora

1050-34

Lisbon

1649-035

Lisbon

4099-001

Porto

4200-319

Porto

03203

Elche

06800

Mérida

07198

Palma de Mallorca

08208

Sabadell

08970

Sant Joan Despí

08221

Terrassa

03010

Alicante

08025

Barcelona

08036

Barcelona

06006

Burgos

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY